# US 2024/0115690 A1 · Mdck suspension cell lines in serum-free, chemically-defined media for vaccine production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0115690 A1
- Document ID: US20240115690A1
- Status: Published application
- Kind: A1
- Application number: 18/143,547
- Filed: 2023-05-04
- Published: 2024-04-11
- Earliest claimed: 2015-09-15
- Assignees: National Health Research Institutes; FUJIFILM Irvine Scientific, Inc.
- Applicants: National Health Research Institutes; Fujifilm Irvine Scientific, Inc.
- Inventors: Jenny BANG; Hsiao-Tzu NI; Alan Yung-Chih HU; Tsai-Chuan WENG
- Web page: https://patentgrep.com/patent/US20240115690A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- C12N 5/0686: {Kidney cells}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A61P 31/16: for influenza or rhinoviruses
- C12N 2015/8518: {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2500/99: Serum-free medium
- C12N 2511/00: Cells for large scale production
- C12N 2513/00: 3D culture
- C12N 2517/02: Cells from transgenic animals
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16051: Methods of production or purification of viral material
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/16251: Methods of production or purification of viral material
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

## Claims

### Claim at position 1

-32. (canceled)

### Claim 33

A method of culturing adapted Madin-Darby canine kidney (MDCK) cells comprising contacting adapted MDCK cells with chemically-defined and animal component free growth medium at 5% CO2.

### Claim 34 (depends on 33)

The method of claim 33, wherein the growth medium comprises from about 20 mM to about 30 mM glucose.

### Claim 35 (depends on 33)

The method of claim 33, wherein the growth medium comprises one or more amino acids selected from L-Serine, L-Arginine HCl, L-Leucine, L-Tyrosine 2Na2H2O, L-Isoleucine, L-Threonine, L-Valine, L-Cysteine HCl H2O, L-Aspartic Acid, L-Glutamic Acid, L-Asparagine, L-Phenylalanine, L-Histidine HCl H2O, L-Methionine, L-Alanine, or L-Tryptophan.

### Claim 36 (depends on 33)

The method of claim 33, wherein the adapted MDCK cells are deposited as DSM ACC3309 with Leibniz-Institut DSMZ-Deutsche Sammlung von Mikro-organismen and Zellkulturen GmbH.

### Claim 37 (depends on 36)

The method of claim 36, wherein the culturing is suspension culturing without microcarriers.

### Claim 38 (depends on 37)

The method of claim 37, wherein the culturing does not require medium exchange or subculturing.

### Claim 39 (depends on 38)

The method of claim 38, wherein the adapted MDCK cells have an average doubling time of between about 30 hours and about 35 hours.

### Claim 40 (depends on 39)

The method of claim 39, wherein the adapted MDCK cells are suitable for producing virus for a human vaccine.

### Claim 41 (depends on 40)

The method of claim 40, wherein the virus maintains antigenicity.

### Claim 42 (depends on 41)

The method of claim 41, wherein the virus is an influenza virus.

### Claim 43

A method for producing an isolated suspension and serum free adapted Madin-Darby canine kidney (MDCK) cell line comprising:
(a) contacting adherent MDCK cells with a growth medium comprising serum for a period of time sufficient to establish the adherent MDCK cells in culture;
(b) contacting the established adherent MDCK cells with chemically-defined growth medium to establish adapted MDCK cells in culture; and
(c) isolating the adapted MDCK cells thereby producing an isolated suspension and serum free adapted MDCK cell line.

### Claim 44 (depends on 43)

The method of claim 43, wherein the contacting of step (b) comprises increasing amounts of the chemically-defined growth medium and decreasing amounts of the serum serially until the chemically-defined growth medium without serum represents all of the medium.

### Claim 45 (depends on 44)

The method of claim 44, wherein the established adherent MDCK cells of step (b) are agitated and in the absence of microcarriers.

### Claim 46 (depends on 45)

The method of claim 45, wherein the isolated suspension and serum free adapted MDCK cell line is deposited as DSM ACC3309 with Leibniz-Institut DSMZ-Deutsche Sammlung von Mikro-organismen and Zellkulturen GmbH.

### Claim 47 (depends on 46)

The method of claim 46, wherein the growth medium comprises between about 1% to about 20% serum.

### Claim 48 (depends on 47)

The method of claim 47, wherein the growth medium comprises 5% serum.

### Claim 49 (depends on 48)

The method of claim 48, wherein the serum is fetal bovine serum (FBS).

### Claim 50 (depends on 49)

The method of claim 49, wherein the isolated suspension and serum free adapted MDCK cell line is suitable for producing a virus for a vaccine.

### Claim 51 (depends on 50)

The method of claim 50, wherein the isolated suspension and serum free adapted MDCK cell line has a doubling time of between about 30 hours and 35 hours.

### Claim 52 (depends on 51)

The method of claim 51, wherein the isolated suspension and serum free adapted MDCK cell line is capable of being cultured in suspension using chemically-defined and animal component free growth medium at 5% CO2.
